{"id":"NCT04156620","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability up to 52 Weeks in Subjects With Active Ankylosing Spondylitis or Non-radiographic Axial SpondyloArthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-12-11","primaryCompletion":"2022-02-17","completion":"2022-12-20","firstPosted":"2019-11-07","resultsPosted":"2024-01-23","lastUpdate":"2024-06-18"},"enrollment":527,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Ankylosing Spondylitis"],"interventions":[{"type":"DRUG","name":"Secukinumab","otherNames":["AIN457"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Secukinumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this global study was to demonstrate the efficacy, safety, and tolerability of an intravenous (i.v.) regimen of secukinumab compared to placebo in participants with active ankylosing spondylitis (AS) or non-radiographic axial spondyloarthritis (nr-axSpA ) at Week 16 despite current or previous non-steroidal anti inflammatory drugs (NSAID), disease-modifying antirheumatic drugs (DMARD) and/or anti Tumor Necrosis Factor (TNF) therapy. In addition, to further support efficacy and safety of an i.v. regimen, data was collected for up to 52 weeks of treatment.","primaryOutcome":{"measure":"Percentage of Participants Who Achieved an ASAS40 (Assessment of SpondyloArthritis International Society Criteria)","timeFrame":"Baseline to Week 16","effectByArm":[{"arm":"AIN457 6 mg/kg - 3 mg/kg i.v.","deltaMin":40.85,"sd":null},{"arm":"Placebo - AIN457 3 mg/kg i.v.","deltaMin":22.94,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":102,"countries":["United States","Belgium","Brazil","Bulgaria","Colombia","Czechia","Greece","Guatemala","India","Italy","Malaysia","Philippines","Poland","Russia","South Korea","Sweden","Thailand","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":["https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=1809"]},"adverseEventsSummary":{"seriousAny":{"events":32,"n":517},"commonTop":["COVID-19","Nasopharyngitis","Upper respiratory tract infection","Headache","Diarrhoea"]}}